(Q31795206)

3 July 2017

title

A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China (English)

1 reference

multicenter clinical trial

3 July 2017

main subject

0 references

Helicobacter pylori

1 reference

based on heuristic

inferred from title

People's Republic of China

0 references

Helicobacter pylori infectious disease

1 reference

Xiao SD

1

1 reference

3 July 2017

Liu WZ

2

1 reference

3 July 2017

Hu PJ

3

1 reference

3 July 2017

Ouyang Q

4

1 reference

3 July 2017

Wang JL

5

1 reference

3 July 2017

Zhou LY

6

1 reference

3 July 2017

Cheng NN

7

1 reference

3 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

Alimentary Pharmacology & Therapeutics

3 July 2017

published in

1 reference

3 July 2017

volume

15

1 reference

3 July 2017

issue

1

1 reference

3 July 2017

page(s)

81-86

1 reference

Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection

3 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00895.X

Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00895.X

High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00895.X

Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00895.X

Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00895.X

Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00895.X

Treatment of peptic ulcer disease with furazolidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00895.X

Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00895.X

Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00895.X

Furazolidone combination therapies for Helicobacter pylori infection in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00895.X

In vitro selection of resistant Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00895.X

Treating Helicobacter pylori--the best is yet to come?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00895.X

Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00895.X

Prevalence of vacuolating cytotoxin production and distribution of distinct vacA alleles in Helicobacter pylori from China

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00895.X

10.1046/J.1365-2036.2001.00895.X

21 January 2018

Identifiers

DOI

1 reference

3 July 2017

1 reference